|
Gene: IGKV3-20 |
Gene summary for IGKV3-20 |
Gene summary. |
Gene information | Species | Human | Gene symbol | IGKV3-20 | Gene ID | 28912 |
Gene name | immunoglobulin kappa variable 3-20 | |
Gene Alias | 13K18 | |
Cytomap | 2p11.2 | |
Gene Type | other | GO ID | GO:0002250 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
28912 | IGKV3-20 | LZE4T | Human | Esophagus | ESCC | 4.00e-05 | 2.08e-01 | 0.0811 |
28912 | IGKV3-20 | LZE22D1 | Human | Esophagus | HGIN | 3.51e-04 | 4.22e+00 | 0.0595 |
28912 | IGKV3-20 | LZE22T | Human | Esophagus | ESCC | 1.27e-02 | 3.85e-01 | 0.068 |
28912 | IGKV3-20 | LZE24T | Human | Esophagus | ESCC | 6.52e-09 | 3.26e-01 | 0.0596 |
28912 | IGKV3-20 | P27T-E | Human | Esophagus | ESCC | 1.22e-02 | 9.33e-02 | 0.1055 |
28912 | IGKV3-20 | P56T-E | Human | Esophagus | ESCC | 8.18e-08 | 8.26e-01 | 0.1613 |
28912 | IGKV3-20 | P57T-E | Human | Esophagus | ESCC | 1.26e-02 | 5.66e-02 | 0.0926 |
28912 | IGKV3-20 | P84T-E | Human | Esophagus | ESCC | 4.23e-04 | 2.41e-01 | 0.0933 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGKV3-20 | SNV | Missense_Mutation | rs11546122 | c.149N>T | p.Ser50Ile | p.S50I | P01619 | IG_V_gene | tolerated(0.05) | benign(0.089) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
IGKV3-20 | SNV | Missense_Mutation | rs774698150 | c.181N>T | p.Pro61Ser | p.P61S | P01619 | IG_V_gene | tolerated(0.11) | possibly_damaging(0.551) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGKV3-20 | SNV | Missense_Mutation | novel | c.310N>G | p.Phe104Val | p.F104V | P01619 | IG_V_gene | tolerated(0.9) | benign(0.031) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGKV3-20 | SNV | Missense_Mutation | novel | c.22C>T | p.Leu8Phe | p.L8F | P01619 | IG_V_gene | tolerated(0.19) | benign(0.018) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGKV3-20 | SNV | Missense_Mutation | novel | c.46N>A | p.Pro16Thr | p.P16T | P01619 | IG_V_gene | tolerated(0.07) | benign(0.113) | TCGA-2Y-A9GS-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
IGKV3-20 | SNV | Missense_Mutation | novel | c.76N>A | p.Gln26Lys | p.Q26K | P01619 | IG_V_gene | deleterious(0) | probably_damaging(0.934) | TCGA-44-2659-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | alimta | PD |
IGKV3-20 | SNV | Missense_Mutation | novel | c.106N>T | p.Gly36Trp | p.G36W | P01619 | IG_V_gene | deleterious(0) | probably_damaging(0.993) | TCGA-55-8514-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGKV3-20 | SNV | Missense_Mutation | novel | c.239N>G | p.Pro80Arg | p.P80R | P01619 | IG_V_gene | deleterious(0) | probably_damaging(0.96) | TCGA-78-8662-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
IGKV3-20 | SNV | Missense_Mutation | novel | c.132G>T | p.Arg44Ser | p.R44S | P01619 | IG_V_gene | deleterious(0.01) | possibly_damaging(0.733) | TCGA-18-5592-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
IGKV3-20 | SNV | Missense_Mutation | novel | c.300N>T | p.Glu100Asp | p.E100D | P01619 | IG_V_gene | deleterious(0.01) | benign(0.163) | TCGA-58-A46L-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |